NEW YORK, Sept. 23 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Sanofi-Aventis: PharmaVitae Profile

http://www.reportlinker.com/p0201760/Sanofi-Aventis-PharmaVitae-Profile.html

Introduction

This analysis examines the historical and forecast performance for Sanofi-Aventis in the pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial per

ABOUT DATAMONITOR HEALTHCARE 2

About the PharmaVitae team 2

Chapter 1 About this profile 3

PharmaVitae Explorer database 3

Chapter structure 3

Executive summary 3

Quarterly update 3

Company introduction 3

Company sales 4

Company financials 4

Key products 4

Data sourcing 4

Sales data 4

Analyst consensus 4

Chapter 2 Executive summary 5

Key findings 5

Prescription pharmaceutical sales and growth rate performance, 2003-15 6

Financial performance, 2003-15 7

Sanofi-Aventis: PharmaVitae forecasts at a glance 8

Strategic insight 9

Diversification is priority for new CEO 9

M&A a key tool to achieve diversification targets 9

Sanofi Pasteur is central to diversified business model 11

Increasing RoW presence is at heart of diversification strategy 12

Parallel diversification occurring across Big Pharma peer set 12

Diversification will struggle to address near-term impact of generic exposure 13

SWOT analysis 14

Strengths 14

Weaknesses 16

Opportunities 16

Threats 18

Table of Contents 20

Table of figures 22

Chapter 3 Quarterly update 23

Latest quarterly sales 23

Latest comment 24

Q1 2010 24

Sanofi-Aventis: Jevtana positioned to help offset Taxotere decline 24

Q4 2009 25

Sanofi-Aventis: CNS franchise takes a knock 25

Sanofi-Aventis: near-term benign prostatic hyperplasia prospects look bleak 25

EASD 2009: Lantus defended amid allegations of increased cancer risk 26

Q3 2009 28

Q2 2009 28

Sanofi-Aventis: Kendrick acquisition expands emerging market presence 28

Latest prescription pharma product news 29

Q1 2010 29

Q4 2009 30

Q3 2009 30

Q2 2009 32

Latest corporate news 34

Q1 2010 34

Q4 2009 35

Q3 2009 35

Q2 2009 36

Future product milestones 37

Chapter 4 Company introduction 39

Key findings 39

M&A history 40

Sanofi-Synthelabo: established in 1999 40

Aventis: result of Hoechst and Rhone-Poulenc merger 41

Sanofi-Aventis: merged in 2004 41

Subsequent M&A promotes diversified business model 41

M&A strategy 43

a) Dilution of exposure to patent expiry risk across blockbuster portfolio 43

b) Establish a diversified business model 43

c) Creation of industry-leading player in the global thrombosis market 43

d) Expansion of geographic presence 44

Current corporate structure 45

Chapter 5 Company sales 47

Key findings 47

Prescription pharmaceutical sales and growth rate analysis, 2003-15 48

Product analysis 50

Product analysis, 2003-09 51

Product analysis, 2009-15 54

Therapy area analysis 60

Geographic analysis 63

Launch/core/expiry analysis 65

Explanation of launch/core/expiry analysis 65

Launch analysis, 2009-15 66

Core analysis, 2009-15 69

Expiry analysis, 2009-15 70

Generics analysis, 2009-15 73

Launch/core/expiry configuration, 2009-15 74

Molecule type analysis 75

Externalization analysis 77

Chapter 6 Company financials 79

Key findings 79

Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003-09 80

Operating costs and profit analysis 81

Operating costs and profit analysis, 2003-09 82

Operating cost ratio and profit margin analysis, 2003-09 83

Operating cost ratio and profit margin analysis, 2009-15 84

Operating costs and profit analysis, 2009-15 85

Chapter 7 Key products 87

Key findings 87

Overview 88

Lantus 89

Overview 89

Sales forecast 90

Lantus uptake encouraged via introduction of competitive administrative devices 90

Link to increased cancer risk casts doubt on future revenue growth 90

Biosimilars pose longer-term threat to revenue 91

Vaccines 92

Overview 92

Sales forecast 93

Vaccines segment divided into five sub-sections 94

Investment in emerging markets to drive revenue expansion 94

Acambis acquisition completed in 2008 94

aflibercept 96

Summary 96

Sales forecast 97

Studies in pancreatic cancer and ovarian cancer discontinued 97

Fierce competition with Avastin in the wider cancer market 97

Aflibercept demonstrates similar side effects to Avastin 98

Presence in oncology field will aid commercialization of aflibercept 98

Lack of prostate cancer-specific clinical trial data 98

The aflibercept/Taxotere combination will have to show a favorable toxicity profile in NSCLC 98

Lack of clinical data makes it difficult to judge aflibercept's clinical efficacy in prostate cancer 99

Lovenox 100

Overview 100

Sales forecast 101

Indication broadening drives revenue growth 101

Sandoz/Momenta's m-enoxaparin likely to launch in 2010 102

Branded competitors also an increasing risk 102

AVE5026 to sustain market position 103

Plavix 104

Overview 104

Sales forecast 105

Sanofi-Aventis holds rights for ex-US markets 105

EU generic launch to impact 5EU and RoW revenue over 2009-15 106

FDA warning issued in 2009: Plavix use with PPIs is discouraged 106

Aprovel/CoAprovel 107

Summary 107

Sales forecast 108

Taxotere 109

Overview 109

Sales forecast 110

Generic competition to impact from 2010 110

Robust position in breast cancer market 110

More competition in NSCLC market 110

Rapid uptake in prostate cancer market 111

Also approved in gastric cancer 111

Most recent approval in head and neck cancer 111

Future revenue growth outlook 112

Eloxatine 113

Overview 113

Sales forecast 114

Sales to decline following generic competition 114

Chapter 8 Appendix 116

References 116

Abbreviations 116

Exchange rates 117

About Datamonitor 118

About Datamonitor Healthcare 118

Datamonitor consulting 118

Disclaimer 120

List of Tables

Table 1: Sanofi-Aventis - PharmaVitae forecasts at a glance 8

Table 2: Sanofi Pasteur vaccines, 2009 11

Table 3: Sanofi-Aventis quarterly sales ($m), Q408-Q409 23

Table 4: Sanofi-Aventis future product milestones, 2010-12 37

Table 5: Sanofi-Aventis product portfolio overview ($m), 2003-09 51

Table 6: Sanofi-Aventis product portfolio overview ($m), 2009-15 54

Table 7: Sanofi-Aventis prescription pharmaceutical sales by therapy area ($m), 2009-15 61

Table 8: Sanofi-Aventis prescription pharmaceutical sales by geographic region ($m), 2009-15 64

Table 9: Sanofi-Aventis launch portfolio overview ($m), 2009-15 66

Table 10: Sanofi-Aventis core portfolio overview ($m), 2009-15 69

Table 11: Sanofi-Aventis expiry portfolio overview ($m), 2009-15 70

Table 12: Sanofi-Aventis generics portfolio overview ($m), 2009-15 73

Table 13: Sanofi-Aventis prescription pharmaceutical sales by molecule type ($m), 2009-15 76

Table 14: Sanofi-Aventis prescription pharmaceutical sales by source ($m), 2009-15 78

Table 15: Total Sanofi-Aventis sales by business unit ($m), 2003-09 80

Table 16: Sanofi-Aventis operating revenue/cost analysis ($m), 2003-09 82

Table 17: Sanofi-Aventis operating cost ratio analysis (% of total revenues), 2003-09 83

Table 18: Sanofi-Aventis operating cost ratio analysis (% of total revenues), 2009-15 84

Table 19: Sanofi-Aventis operating revenue/cost analysis ($m), 2009-15 85

Table 20: Sanofi-Aventis Key products overview 88

Table 21: Lantus: overview 89

Table 22: Lantus: sales forecast ($m), 2009-15 90

Table 23: Vaccines: overview 92

Table 24: Vaccines by indication: sales forecast ($m), 2009-15 93

Table 25: aflibercept: overview 96

Table 26: aflibercept: sales forecast ($m), 2009-15 97

Table 27: Lovenox: overview 100

Table 28: Lovenox: sales forecast ($m), 2009-15 101

Table 29: Plavix: overview 104

Table 30: Plavix: sales forecast ($m), 2009-15 105

Table 31: Aprovel/CoAprovel: overview 107

Table 32: Aprovel/CoAprovel: sales forecast ($m), 2009-15 108

Table 33: Taxotere: overview 109

Table 34: Taxotere: sales forecast ($m), 2009-15 110

Table 35: Eloxatine: overview 113

Table 36: Eloxatine: sales forecast ($m), 2009-15 114

Table 37: Exchange rates, 2010 117

List of Figures

Figure 1: The PharmaVitae Explorer 3

Figure 2: Sanofi-Aventis prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003-15 6

Figure 3: Sanofi-Aventis's financial performance ($m), 2003-15 7

Figure 4: Sanofi-Aventis acquisitions, 2008-10 10

Figure 5: Big Pharma peer set ranked by prescription pharma RoW sales ($m), 2003-15 12

Figure 6: Sanofi-Aventis absolute sales growth ($m) by launch/core/expiry versus Big Pharma peer set, 2009-15 13

Figure 7: Sanofi-Aventis SWOT analysis 14

Figure 8: M&A history 40

Figure 9: Current corporate structure 45

Figure 10: Sanofi-Aventis business unit revenue contribution, 2009 46

Figure 11: Sanofi-Aventis prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003-15 48

Figure 12: Sanofi-Aventis key product sales ($m), 2003-15 50

Figure 13: Sanofi-Aventis key sales growth drivers and resistors ($m), 2003-09 53

Figure 14: Sanofi-Aventis key sales growth drivers and resistors ($m), 2009-15 57

Figure 15: Sanofi-Aventis prescription pharmaceutical sales by therapy area ($m), 2003-15 60

Figure 16: Sanofi-Aventis prescription pharmaceutical sales by geographic region ($m), 2003-15 63

Figure 17: Sanofi-Aventis launch/core/expiry configuration ($m), 2009-15 74

Figure 18: Sanofi-Aventis prescription pharmaceutical sales by molecule type ($m), 2003-15 75

Figure 19: Sanofi-Aventis prescription pharmaceutical sales by source ($m), 2003-15 77

Figure 20: Sanofi-Aventis operating revenue/cost analysis ($m), 2003-15 81

Figure 21: Sanofi Pasteur vaccines revenue by sub-section, 2009 94

To order this report:

Pharmaceutical Industry: Sanofi-Aventis: PharmaVitae Profile

Pharmaceutical Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker

Back to top

RELATED LINKS
http://www.reportlinker.com